SI2552966T1 - Protitelesa proti csf-1r - Google Patents
Protitelesa proti csf-1rInfo
- Publication number
- SI2552966T1 SI2552966T1 SI201131235T SI201131235T SI2552966T1 SI 2552966 T1 SI2552966 T1 SI 2552966T1 SI 201131235 T SI201131235 T SI 201131235T SI 201131235 T SI201131235 T SI 201131235T SI 2552966 T1 SI2552966 T1 SI 2552966T1
- Authority
- SI
- Slovenia
- Prior art keywords
- antibodies against
- against csf
- csf
- antibodies
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39541—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A61K2039/507—Comprising a combination of two or more separate antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/77—Internalization into the cell
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Microbiology (AREA)
- Oncology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Mycology (AREA)
- Biomedical Technology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Hematology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US31989610P | 2010-04-01 | 2010-04-01 | |
| PCT/US2011/030148 WO2011123381A1 (en) | 2010-04-01 | 2011-03-28 | Antibodies against csf-1r |
| EP11713416.3A EP2552966B1 (en) | 2010-04-01 | 2011-03-28 | Antibodies against csf-1r |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SI2552966T1 true SI2552966T1 (sl) | 2017-08-31 |
Family
ID=44010222
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SI201131235T SI2552966T1 (sl) | 2010-04-01 | 2011-03-28 | Protitelesa proti csf-1r |
Country Status (30)
| Country | Link |
|---|---|
| US (1) | US8263079B2 (enExample) |
| EP (2) | EP2552966B1 (enExample) |
| JP (1) | JP5767310B2 (enExample) |
| KR (1) | KR101439719B1 (enExample) |
| CN (1) | CN102834414B (enExample) |
| AR (1) | AR080698A1 (enExample) |
| AU (1) | AU2011232850B2 (enExample) |
| BR (1) | BR112012024564A2 (enExample) |
| CA (1) | CA2795081C (enExample) |
| CY (1) | CY1119324T1 (enExample) |
| DK (1) | DK2552966T3 (enExample) |
| EA (1) | EA021600B1 (enExample) |
| ES (1) | ES2640909T3 (enExample) |
| HR (1) | HRP20171153T1 (enExample) |
| HU (1) | HUE036379T2 (enExample) |
| IL (1) | IL222222A (enExample) |
| JO (1) | JO3291B1 (enExample) |
| LT (1) | LT2552966T (enExample) |
| ME (1) | ME02806B (enExample) |
| MX (1) | MX2012011234A (enExample) |
| NZ (1) | NZ602621A (enExample) |
| PL (1) | PL2552966T3 (enExample) |
| PT (1) | PT2552966T (enExample) |
| RS (1) | RS56219B1 (enExample) |
| SG (1) | SG183829A1 (enExample) |
| SI (1) | SI2552966T1 (enExample) |
| TW (1) | TWI402078B (enExample) |
| UA (1) | UA111818C2 (enExample) |
| WO (1) | WO2011123381A1 (enExample) |
| ZA (1) | ZA201206926B (enExample) |
Families Citing this family (68)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SI2510010T1 (sl) | 2009-12-10 | 2016-02-29 | F. Hoffmann-La Roche Ag | Protitelesa, vezavna na ekstracelično domeno 4 humanega csf1r in njihova uporaba |
| US10626399B2 (en) | 2010-01-28 | 2020-04-21 | The Board Of Trustees Of The Leland Stanford Junior University | Methods of treating cognitive symptoms of an aging-associated impairment by modulating C-C chemokine receptor type 3 (CCR3) |
| US10487148B2 (en) | 2010-01-28 | 2019-11-26 | The Board Of Trustees Of The Leland Stanford Junior University | Methods and compositions for treating aging-associated impairments |
| US20160208011A1 (en) | 2010-01-28 | 2016-07-21 | The Board Of Trustees Of The Leland Stanford Junior University | Ccr3 modulation in the treatment of aging-associated impairments, and compositions for practicing the same |
| JP2013521765A (ja) | 2010-03-05 | 2013-06-13 | エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト | ヒトｃｓｆ−１ｒに対する抗体及びその使用 |
| RU2617966C2 (ru) | 2010-03-05 | 2017-04-28 | Ф.Хоффманн-Ля Рош Аг | Антитела против csf-1r человека и их применение |
| HRP20190047T1 (hr) | 2010-05-04 | 2019-02-22 | Five Prime Therapeutics, Inc. | Protutijela koja se vežu na csf1r |
| US9161968B2 (en) * | 2011-04-08 | 2015-10-20 | The Board Of Trustees Of The Leland Stanford Junior University | Methods of neuroprotection involving macrophage colony stimulating factor receptor agonists |
| MX356337B (es) * | 2011-12-15 | 2018-05-23 | Hoffmann La Roche | Anticuerpos contra csf-1r humano y sus usos. |
| MX2014008961A (es) * | 2012-02-06 | 2014-10-14 | Genentech Inc | Composiciones y metodos para utilizar inhibidores de csf1r. |
| AR090263A1 (es) * | 2012-03-08 | 2014-10-29 | Hoffmann La Roche | Terapia combinada de anticuerpos contra el csf-1r humano y las utilizaciones de la misma |
| US20130302322A1 (en) | 2012-05-11 | 2013-11-14 | Five Prime Therapeutics, Inc. | Methods of treating conditions with antibodies that bind colony stimulating factor 1 receptor (csf1r) |
| SG10201906328RA (en) | 2012-08-31 | 2019-08-27 | Five Prime Therapeutics Inc | Methods of treating conditions with antibodies that bind colony stimulating factor 1 receptor (csf1r) |
| AR095882A1 (es) | 2013-04-22 | 2015-11-18 | Hoffmann La Roche | Terapia de combinación de anticuerpos contra csf-1r humano con un agonista de tlr9 |
| GB201315487D0 (en) | 2013-08-30 | 2013-10-16 | Ucb Pharma Sa | Antibodies |
| AR097584A1 (es) | 2013-09-12 | 2016-03-23 | Hoffmann La Roche | Terapia de combinación de anticuerpos contra el csf-1r humano y anticuerpos contra el pd-l1 humano |
| BR112016012968A2 (pt) | 2013-12-09 | 2017-08-08 | Univ Leland Stanford Junior | Métodos e composições para o tratamento de condições associadas com o envelhecimento |
| US10905779B2 (en) | 2013-12-09 | 2021-02-02 | The Board Of Trustees Of The Leland Stanford Junior University | Methods for screening human blood products comprising plasma using immunocompromised rodent models |
| KR102000224B1 (ko) * | 2014-02-03 | 2019-07-16 | 전대연 | 스마트 이메일 관리방법 |
| MX391735B (es) | 2014-06-23 | 2025-03-21 | Five Prime Therapeutics Inc | Anticuerpos que se enlazan al receptor del factor 1 estimulador de colonias (csf1r) y sus usos en el tratamiento de trastornos por cd16+ |
| WO2016069727A1 (en) | 2014-10-29 | 2016-05-06 | Five Prime Therapeutics, Inc. | Combination therapy for cancer |
| CN107257806B (zh) | 2014-12-22 | 2021-08-10 | 戊瑞治疗有限公司 | 用于治疗pvns的抗csf1r抗体 |
| RS61531B1 (sr) | 2015-04-13 | 2021-04-29 | Five Prime Therapeutics Inc | Kombinovana terapija za kancer |
| CN107660152B (zh) | 2015-05-27 | 2021-11-05 | Ucb生物制药私人有限公司 | 用于治疗神经系统疾病的方法 |
| KR20240025721A (ko) | 2015-06-15 | 2024-02-27 | 더 보드 어브 트러스티스 어브 더 리랜드 스탠포드 주니어 유니버시티 | 노화와 연관된 질환을 치료하기 위한 방법 및 조성물 |
| JP6621252B2 (ja) * | 2015-06-17 | 2019-12-18 | 国立大学法人北海道大学 | 治療耐性がんに対する治療耐性低減剤 |
| JP6811733B2 (ja) * | 2015-06-24 | 2021-01-13 | エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト | リンパ腫又は白血病におけるリンパ球増加症を誘導することにおける使用のためのヒトｃｓｆ−１ｒに対する抗体 |
| EP3108897A1 (en) * | 2015-06-24 | 2016-12-28 | F. Hoffmann-La Roche AG | Antibodies against human csf-1r for use in inducing lymphocytosis in lymphomas or leukemias |
| EP3973988A1 (en) | 2015-11-04 | 2022-03-30 | Duke University | Combination therapy of immunotoxin and checkpoint inhibitor |
| WO2017085566A1 (en) * | 2015-11-20 | 2017-05-26 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods and compositions for increase/induction of immune responses |
| EP3380521A1 (en) * | 2015-11-24 | 2018-10-03 | Eli Lilly and Company | Combination therapy for cancer |
| MA44309A (fr) * | 2015-11-25 | 2018-10-03 | Nogra Pharma Ltd | Oligonucléotides antisens il-34 et leurs procédés d'utilisation |
| ES2975517T3 (es) | 2016-04-28 | 2024-07-08 | Alkahest Inc | Fracciones de plasma como terapia para el cáncer de timo |
| JP7461741B2 (ja) | 2016-06-20 | 2024-04-04 | カイマブ・リミテッド | 抗ｐｄ－ｌ１およびｉｌ－２サイトカイン |
| JP7138094B2 (ja) | 2016-08-25 | 2022-09-15 | エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト | マクロファージ活性化剤と組み合わせた抗ｃｓｆ－１ｒ抗体の間欠投与 |
| AR109770A1 (es) | 2016-10-18 | 2019-01-23 | Lilly Co Eli | ANTICUERPOS DEL RECEPTOR II DE TGF-b |
| EA039316B1 (ru) | 2016-10-24 | 2022-01-12 | Алкахест, Инк. | Фракции плазмы крови в качестве лечения когнитивных расстройств, связанных со старением |
| WO2018115051A1 (en) | 2016-12-22 | 2018-06-28 | F. Hoffmann-La Roche Ag | Treatment of tumors with an anti-csf-1r antibody in combination with an anti-pd-l1 antibody after failure of anti-pd-l1/pd1 treatment |
| WO2018144334A1 (en) | 2017-02-02 | 2018-08-09 | Imclone Llc | Dosing regimen for anti-csf-1r antibody |
| WO2018183366A1 (en) | 2017-03-28 | 2018-10-04 | Syndax Pharmaceuticals, Inc. | Combination therapies of csf-1r or csf-1 antibodies and a t-cell engaging therapy |
| US12134654B2 (en) | 2017-04-19 | 2024-11-05 | Marengo Therapeutics, Inc. | Multispecific molecules and uses thereof |
| US11040068B2 (en) | 2017-04-26 | 2021-06-22 | Alkahest, Inc. | Dosing regimen for treatment of cognitive and motor impairments with blood plasma and blood plasma products |
| DK3615057T3 (da) | 2017-04-26 | 2024-01-02 | Alkahest Inc | Doseringsskema til behandling af kognitive svækkelser med blodplasmaprodukter |
| JP7537874B2 (ja) | 2017-05-19 | 2024-08-21 | シンダックス ファーマシューティカルズ， インコーポレイテッド | 併用療法 |
| WO2019040780A1 (en) | 2017-08-25 | 2019-02-28 | Five Prime Therapeutics Inc. | ANTI-B7-H4 ANTIBODIES AND METHODS OF USE |
| MX2020002301A (es) | 2017-09-13 | 2020-07-13 | Five Prime Therapeutics Inc | Terapia de combinacion de anticuerpos anti receptor del factor estimulante de colonias 1 (csf1r) y anti proteina de muerte programada 1 (pd-1) combinados para cancer pancreatico. |
| EP3720881A1 (en) | 2017-12-08 | 2020-10-14 | Elstar Therapeutics, Inc. | Multispecific molecules and uses thereof |
| AU2019226011B2 (en) | 2018-02-21 | 2025-11-27 | Five Prime Therapeutics, Inc. | B7-H4 antibody formulations |
| GB201803226D0 (en) * | 2018-02-28 | 2018-04-11 | Ultrahuman Twelve Ltd | CSF1R Binding agents |
| CN111971308A (zh) | 2018-03-02 | 2020-11-20 | 戊瑞治疗有限公司 | B7-h4抗体及其使用方法 |
| BR112020018709A2 (pt) | 2018-03-28 | 2021-01-05 | Bristol-Myers Squibb Company | Proteínas de fusão do receptor alfa de interleucina-2/interleucina-2 e métodos de uso |
| US12103974B2 (en) * | 2018-05-23 | 2024-10-01 | Beigene, Ltd. | Anti-OX40 antibodies and methods of use |
| CN108948200B (zh) * | 2018-07-18 | 2019-05-10 | 博奥信生物技术（南京）有限公司 | 一种抗人csf-1r单克隆抗体及其应用 |
| CN108948201B (zh) * | 2018-07-18 | 2019-05-07 | 博奥信生物技术（南京）有限公司 | 抗人csf-1r单克隆抗体及应用 |
| CN109096397B (zh) * | 2018-07-18 | 2019-04-16 | 博奥信生物技术（南京）有限公司 | 一种抗人csf-1r单克隆抗体及应用 |
| US12258398B2 (en) | 2018-07-27 | 2025-03-25 | Alector Llc | Anti-Siglec-5 antibodies and methods of use thereof |
| CN113164777B (zh) | 2018-09-27 | 2024-12-13 | 马伦戈治疗公司 | Csf1r/ccr2多特异性抗体 |
| JP7504090B2 (ja) | 2018-10-26 | 2024-06-21 | アルカヘスト，インコーポレイテッド | 疼痛、創傷治癒及び術後回復の改善のための血漿及び血漿画分の使用 |
| US12043668B2 (en) | 2018-12-13 | 2024-07-23 | Development Center For Biotechnology | Anti-human CSF-1R antibody and uses thereof |
| ES2984122T3 (es) * | 2019-03-05 | 2024-10-29 | Inserm Institut National De La Santeet De La Rech Medicale | Biomarcadores para carcinoma de células renales |
| WO2020232051A1 (en) * | 2019-05-15 | 2020-11-19 | Biosion Inc. | Antibody binding csf-1r and use thereof |
| CN113811331A (zh) * | 2019-05-24 | 2021-12-17 | 安立玺荣生医(香港)有限公司 | 抗csf1r抗体、il10融合蛋白及其用途 |
| CN110499295A (zh) * | 2019-09-11 | 2019-11-26 | 宝船生物医药科技(上海)有限公司 | 一种csf-1r报告基因细胞株及其制备方法和应用 |
| EP4034558A1 (en) | 2019-09-26 | 2022-08-03 | Roche Diagnostics GmbH | Anti-csf-1r antibody |
| EP4045086A4 (en) * | 2019-10-17 | 2024-05-15 | National Health Research Institutes | USE OF SUCCINATE AS A BIOMARKER IN THE DIAGNOSIS AND TREATMENT OF CANCER |
| KR102373965B1 (ko) * | 2020-06-05 | 2022-03-15 | (주)지아이이노베이션 | Ｉｌ-２ 단백질 및 ｃｄ８０ 단백질을 포함하는 융합단백질을 포함하는 방사선 치료 증진용 약학적 조성물 |
| CN115806626B (zh) * | 2022-06-21 | 2024-02-23 | 四川大学华西医院 | 一种基于csf1的嵌合抗原受体免疫细胞制备及其应用 |
| AU2024274397A1 (en) | 2023-05-17 | 2025-11-13 | Syndax Pharmaceuticals, Inc. | Methods of treating chronic graft-versus-host disease-related bronchiolitis obliterans syndrome using an anti-colony stimulating factor 1 receptor antibody |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB8607679D0 (en) | 1986-03-27 | 1986-04-30 | Winter G P | Recombinant dna product |
| IL89489A0 (en) | 1988-03-09 | 1989-09-10 | Hybritech Inc | Chimeric antibodies directed against human carcinoembryonic antigen |
| FI895955A0 (fi) | 1988-04-15 | 1989-12-13 | Protein Design Labs Inc | Il-2-receptorspecifika chimera antikroppar. |
| ES2070172T3 (es) | 1988-04-16 | 1995-06-01 | Celltech Ltd | Procedimiento para producir proteinas mediante adn recombinante. |
| JPH0967400A (ja) | 1995-08-31 | 1997-03-11 | Toray Ind Inc | モノクローナル抗体、該抗体を産生するハイブリドーマ及びその利用 |
| DK1572106T3 (da) | 2002-11-15 | 2010-08-23 | Novartis Vaccines & Diagnostic | Fremgangsmåde til forebyggelse og behandling af cancermetastase og knogletab forbundet med cancermetastase |
| US20090110681A1 (en) | 2005-03-08 | 2009-04-30 | Pfizer, Inc. | Anti-M-CSF Antibody Compositions |
| PT2188313T (pt) * | 2007-08-21 | 2017-12-12 | Amgen Inc | Proteínas de ligação ao antigénio c-fms humano |
| EP2262836B1 (en) * | 2008-03-14 | 2016-03-09 | Transgene SA | Antibody against the csf-1 r |
-
2011
- 2011-03-21 AR ARP110100905A patent/AR080698A1/es unknown
- 2011-03-22 JO JOP/2011/0097A patent/JO3291B1/ar active
- 2011-03-25 TW TW100110442A patent/TWI402078B/zh not_active IP Right Cessation
- 2011-03-28 LT LTEP11713416.3T patent/LT2552966T/lt unknown
- 2011-03-28 UA UAA201210763A patent/UA111818C2/uk unknown
- 2011-03-28 RS RS20170817A patent/RS56219B1/sr unknown
- 2011-03-28 US US13/073,004 patent/US8263079B2/en not_active Expired - Fee Related
- 2011-03-28 ME MEP-2017-174A patent/ME02806B/me unknown
- 2011-03-28 SI SI201131235T patent/SI2552966T1/sl unknown
- 2011-03-28 EP EP11713416.3A patent/EP2552966B1/en active Active
- 2011-03-28 DK DK11713416.3T patent/DK2552966T3/en active
- 2011-03-28 CN CN201180017294.3A patent/CN102834414B/zh not_active Expired - Fee Related
- 2011-03-28 EP EP16196811.0A patent/EP3156419A1/en not_active Withdrawn
- 2011-03-28 PL PL11713416T patent/PL2552966T3/pl unknown
- 2011-03-28 HU HUE11713416A patent/HUE036379T2/hu unknown
- 2011-03-28 JP JP2013502691A patent/JP5767310B2/ja not_active Expired - Fee Related
- 2011-03-28 HR HRP20171153TT patent/HRP20171153T1/hr unknown
- 2011-03-28 AU AU2011232850A patent/AU2011232850B2/en not_active Ceased
- 2011-03-28 NZ NZ602621A patent/NZ602621A/en not_active IP Right Cessation
- 2011-03-28 EA EA201270732A patent/EA021600B1/ru not_active IP Right Cessation
- 2011-03-28 PT PT117134163T patent/PT2552966T/pt unknown
- 2011-03-28 CA CA2795081A patent/CA2795081C/en not_active Expired - Fee Related
- 2011-03-28 WO PCT/US2011/030148 patent/WO2011123381A1/en not_active Ceased
- 2011-03-28 SG SG2012064135A patent/SG183829A1/en unknown
- 2011-03-28 ES ES11713416.3T patent/ES2640909T3/es active Active
- 2011-03-28 BR BR112012024564A patent/BR112012024564A2/pt not_active Application Discontinuation
- 2011-03-28 KR KR1020127025707A patent/KR101439719B1/ko not_active Expired - Fee Related
- 2011-03-28 MX MX2012011234A patent/MX2012011234A/es active IP Right Grant
-
2012
- 2012-09-14 ZA ZA2012/06926A patent/ZA201206926B/en unknown
- 2012-09-27 IL IL222222A patent/IL222222A/en not_active IP Right Cessation
-
2017
- 2017-09-07 CY CY20171100949T patent/CY1119324T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL222222A0 (en) | Antibodies against csf-1r | |
| AP4082A (en) | Anti-cd40 antibodies | |
| ZA201209004B (en) | Anti-fgfr2 antibodies | |
| GB201000467D0 (en) | Antibodies | |
| IL221371A0 (en) | Anti-lrp6 antibodies | |
| IL220404A (en) | Antiseptic antibodies | |
| ZA201306869B (en) | Antibody against the csf-1r | |
| PT2581113T (pt) | Anticorpo anti-tim-3 | |
| PL3342786T3 (pl) | Przeciwciało przeciwko dll3 | |
| PL2616489T3 (pl) | Przeciwciało anty-huTNFR1 | |
| PL2603528T3 (pl) | Przeciwciała Fab-glikozylowane | |
| GB201020738D0 (en) | Antibodies | |
| ZA201302459B (en) | Antibodies | |
| GB201002238D0 (en) | Antibodies | |
| GB201007957D0 (en) | Antibody | |
| GB201005062D0 (en) | Antibodies | |
| GB201020751D0 (en) | Antibodies | |
| GB201017780D0 (en) | Antibody |